🖼
Figure 3 — TFE3-Rearranged and TFEB-Altered Renal Cell Carcinomas: Molecular Landscape and
active
paper figure
Created: 2026-04-21T18:29:40
By: paper_figures_tool
Quality:
50%
🔗 External
ID: paper-fig-paper-41899560-3
Figure 3Figure 3
Suggested diagnostic workflow for suspected MiT family renal cell carcinoma (MiT-RCC). The algorithm integrates clinical-pathologic suspicion, confirmation of renal origin, an immunohistochemistry (IHC) screening panel ( TFE3 , TFEB , and GPNMB), confirmatory break-apart fluorescence in situ hybridization (FISH) for rearrangements where appropriate, and advanced molecular testing (RNA-based fusion assays, TRIM63 RNA in situ hybridization (RNA-ISH), and copy-number assessment for TFEB / VEGFA amplification) in equivocal cases. Abbreviations: EMA, epithelial membrane antigen; FISH, fluorescence in situ hybridization; GPNMB, glycoprotein NMB; IHC, immunohistochemistry; panCK, pancytokeratin; PAX2, paired box gene 2; PAX8, paired box gene 8; PEComa, perivascular epithelioid cell neoplasm; RNA-ISH, RNA in situ hybridization; RT-PCR, reverse transcription polymerase chain reaction; SMA, smooth muscle actin; S100, S100 protein; SOX10, SRY-box transcription factor 10; VEGFA , vascular en
▸Metadata
| pmid | paper-41899560 |
| caption | Suggested diagnostic workflow for suspected MiT family renal cell carcinoma (MiT-RCC). The algorithm integrates clinical-pathologic suspicion, confirmation of renal origin, an immunohistochemistry (IH |
| image_url | https://www.ebi.ac.uk/europepmc/articles/PMC13025244/bin/cancers-18-00958-g003.jpg |
| paper_title | TFE3-Rearranged and TFEB-Altered Renal Cell Carcinomas: Molecular Landscape and Therapeutic Advances. |
| figure_label | Figure 3 |
| figure_number | 3 |
| _schema_version | 1 |
| source_strategy | pmc_api |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.